Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 12/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 10/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823656 | 0.87 | HDAC4 (0.65) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL823555 | 0.87 | HDAC4 (0.65) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL823655 | 0.87 | HDAC4 (0.65) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL823563 | 0.87 | HDAC4 (0.65) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL823592 | 0.86 | HDAC3 (0.56) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL13816931 | 0.86 | HDAC1 (0.67) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL823572 | 0.86 | HDAC3 (0.58) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL3626901 | 0.84 | HDAC3 (0.64) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL14987895 | 0.82 | HDAC3 (0.64) | HDAC3HDAC1HDAC4HDAC7HDAC2 | |
| SCHEMBL5239381 | 0.81 | HDAC1 (0.74) | HDAC3HDAC1HDAC4HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| EP-2714924-B1 | HDAC Inhibitors for use in the treatment of Gaucher's disease, von Hippel-Lindau disease, phaeochromocytoma and paragangliomas. | LIXTE BIOTECHNOLOGY INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2318005-B1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY INC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2200439-B1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY INC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2010014220-A1 | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| US-20090143445-A1 | HDAC Inhibitors | JOHN P. WHITE, ESQ | 2009-06-04 | — | — | US | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045440-A1 | HDAC INHIBITORS | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009020565-A1 | USE OF PHOSPHATES TO TREAT NEUROBLASTOMAS AND MEDULLOGASTOMAS | LIXTE BIOTECHNOLOGY, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029640-A1 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | SNCA, NLN, HTT | HDAC3 429/4885HDAC1 417/4885HDAC4 191/4885 |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HDAC3 1962/4885HDAC1 1805/4885HDAC4 2320/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC3 3028/4885HDAC1 1578/4885HDAC4 2054/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HDAC3 3028/4885HDAC1 1578/4885HDAC4 2054/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | HDAC3 2178/4885HDAC1 2341/4885HDAC4 2401/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HDAC3 1324/4885HDAC1 927/4885HDAC4 785/4885 |
| US-20090143445-A1 | HDAC Inhibitors | HDAC3, HDAC7, HDAC4 | HDAC3 1/4885HDAC1 6/4885HDAC4 3/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | HDAC3 1673/4885HDAC1 650/4885HDAC4 1375/4885 |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | PPME1, PNKP, PPP6C | HDAC3 120/4885HDAC1 18/4885HDAC4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.